Regulatory Novo Nordisk preps filings for sickle cell drug etavopivat PharmaphorumNovo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.RegulatoryHematologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease. RegulatoryHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new dataNext: Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
